

Figure S1 Continuous GM-CSF stimulation has a cumulative effect on dendritic cells *in vitro*. (a) The dendritic cell line DC2.4 in culture was treated with GM-CSF for one, two, and three days. The cells were immunostained for MHC-II, CD40, CD80, and CD86 and analyzed by FACS. Shown is one of the three independent experiments with similar results.




Figure S2 The effects of continuous GM-CSF stimulation on dendritic cells in lymph nodes (\mathbf{a} , \mathbf{b}) and spleens (\mathbf{c} , \mathbf{d}). Mice were subcutaneously injected with $10\mu g$ of GM-CSF for one, two, and three days or with $30\mu g$ of GM-CSF for one day. Spleen and lymph node cells were isolated on day 4, and FACS analysis was performed to determine the percentage of cells with a myeloid DC phenotype (stained with CD11c-FITC, CD11b-PB, and MHC-II-PE). The percentage of double-stained cells identified is shown. Results are from a single representative experiment (*p < 0.05, **p < 0.01)




Figure S3 Specific immunostaining of HBsAg in HBV transgenic mice and wild-type (WT) mice at 14 days after the third immunization. Liver sections were examined after specific immunostaining of HBsAg. Objective amplification from left to right is 400æ. (a) Liver of naïve HBsAg-Tg mice. (b) Liver from the æGM-CSF+rHBVvac group after the third immunization. (c) Liver of naïve WT mice (C57BL/6). Data are expressed as mean \pm SEM (n = 5) (***p < 0.001).